Core Viewpoint - LENZ Therapeutics, Inc. (LENZ) has experienced a bearish price trend recently, losing 5.3% over the past week, but the formation of a hammer chart pattern suggests a potential trend reversal as buying interest may be increasing [1] Technical Analysis - The hammer chart pattern indicates a possible bottom formation, suggesting that selling pressure may be subsiding, which could lead to a trend reversal [1] - A hammer pattern typically forms during a downtrend when the stock opens lower, makes a new low, but then closes near or slightly above the opening price, indicating that bears may be losing control [2] Fundamental Analysis - There has been a positive trend in earnings estimate revisions for LENZ, with the consensus EPS estimate increasing by 33.6% over the last 30 days, indicating strong agreement among analysts about the company's potential for better earnings [3] - LENZ currently holds a Zacks Rank 2 (Buy), placing it in the top 20% of over 4,000 ranked stocks, which historically outperform the market [3] - The Zacks Rank serves as a timing indicator, suggesting that LENZ's prospects are beginning to improve, further supporting the case for a potential trend reversal [3]

Company Overview - LENZ Therapeutics, Inc. is a pre-commercial biopharmaceutical company focused on developing and commercializing the first and only aceclidine-based eye drop aimed at improving near vision in individuals with presbyopia [5] - The product candidate, LNZ100, is a preservative-free, single-use, once-daily eye drop containing aceclidine, which has been evaluated in the Phase 3 CLARITY study [5] - Presbyopia affects an estimated 1.8 billion people globally, including 128 million in the United States [5] - The FDA has set a Prescription Drug User Fee Act (PDUFA) target action date of August 8, 2025, for LNZ100 [5] Upcoming Investor Conferences - Company management will participate in the Jefferies London Healthcare Conference from November 19th to November 21st, 2024, with one-on-one meetings scheduled [1] - Management is scheduled for a fireside chat at the Piper Sandler 36th Annual Healthcare Conference on December 3rd, 2024, at 3:30 PM ET, along with one-on-one meetings [2] - At the 7th Annual Evercore HealthCONx Conference on December 4th, 2024, management will also participate in a fireside chat at 7:30 AM ET and one-on-one meetings [2] - Management will take part in a panel discussion titled "Eyes Wide Open on Ophthalmology" at the Citi 2024 Global Healthcare Conference on December 5th, 2024, at 1:45 PM ET, along with one-on-one meetings [3] Webcast Information - A live audio webcast of the Piper Sandler Healthcare Conference fireside chat will be available on the LENZ Therapeutics website, with a replay accessible for 12 months following the event [4]

Company Overview - LENZ Therapeutics, Inc. currently holds a Momentum Style Score of A, indicating strong momentum characteristics [2] - The company has a Zacks Rank of 2 (Buy), suggesting a favorable outlook compared to the market [3] Price Performance - Over the past week, LENZ shares have increased by 3.37%, while the Zacks Medical - Biomedical and Genetics industry has decreased by 0.75% [5] - In the last month, LENZ's price has risen by 41.93%, significantly outperforming the industry's 2.78% [5] - Over the past quarter, LENZ shares have surged by 54.15%, and they have increased by 114.17% over the last year, compared to the S&P 500's gains of 13.08% and 38.58%, respectively [6] Trading Volume - LENZ's average 20-day trading volume is 177,779 shares, which serves as a baseline for price-to-volume analysis [7] Earnings Outlook - In the past two months, 4 earnings estimates for LENZ have been revised upwards, while none have been revised downwards, leading to an increase in the consensus estimate from -$2.29 to -$2.09 [9] - For the next fiscal year, 5 estimates have moved upwards with no downward revisions during the same period [9]

Financial Data and Key Metrics Changes - The company ended Q3 2024 with approximately $217.2 million in cash, cash equivalents, and marketable securities, which is expected to fund operations until post-launch positive cash flow [45] - Total operating expenses for Q3 2024 were approximately $12.9 million, a decrease from $19.9 million in the same period in 2023 [46] - Q3 2024 cash burn, net of interest income, was approximately $9 million, down from $14.4 million in Q2 2024 [46] - Net loss per share was $0.38 in Q3 2024, compared to $9.62 in Q3 2023, reflecting a significant reduction in losses [51][53] Business Line Data and Key Metrics Changes - Total R&D expenses decreased to $6.5 million in Q3 2024 from $17 million in Q3 2023, reflecting a shift in focus towards pre-approval manufacturing activities [48] - SG&A expenses increased to $6.5 million in Q3 2024 from $2.9 million in Q3 2023, driven by increases in commercial headcount and pre-commercial planning activities [48] Market Data and Key Metrics Changes - Presbyopia impacts an estimated 128 million people in the U.S., representing a significant market opportunity [26] - The company aims to provide access to an estimated 400 million presbyopes in China, highlighting the global potential of LNZ100 [22] Company Strategy and Development Direction - The company is transitioning from a late-stage clinical development biopharmaceutical company to a pre-commercial company, focusing on the potential approval and launch of LNZ100 [8][23] - The commercial strategy is based on three pillars: ensuring doctors recommend the product, encouraging consumers to request it by name, and ensuring ease of product access [40][41] Management's Comments on Operating Environment and Future Outlook - Management expressed confidence in the upcoming FDA approval and the potential launch of LNZ100, which is expected to be the first aceclidine-based eye drop for presbyopia [55] - The company is preparing for a potential commercial launch in the U.S. as early as Q4 2025, following the PDUFA date of August 8, 2025 [19][19] Other Important Information - The FDA accepted the NDA for LNZ100, with a PDUFA target action date set for August 8, 2025 [9][17] - The company has completed a $30 million PIPE financing, strengthening its balance sheet [44] Q&A Session Summary Question: Were the survey conclusions consistent among optometrists and ophthalmologists? - Management confirmed that the feedback across the two groups was consistent, reflecting the 80/20 split in the survey [58] Question: What level of investment in social media and influencers is expected for the launch? - The company plans to invest significantly in direct-to-consumer strategies, including influencer campaigns, to maximize market potential [61] Question: Where is the product manufactured? - Manufacturing is set up at both U.S. and European facilities, ensuring commercial scale production [60] Question: What incentives do optometrists have to recommend the product? - The product provides an ideal solution for presbyopia, which is a significant market need, thus incentivizing recommendations [66] Question: How does the company expect the launch to compare to VUITY? - Management anticipates a strong launch, leveraging lessons learned from VUITY's initial success and subsequent challenges [66][90] Question: What is the timeline for approval in China? - The company is not guiding on the timeline for approval in China but is optimistic about the market potential [83] Question: How will the company target specific presbyopic groups? - The company plans to focus on contact lens wearers, individuals who have had refractive surgery, and those who visit med spas [108] Question: When will the sales force be fully operational? - The sales force is being built out ahead of the PDUFA date, with key hires already in place [114]

Table of Contents _________________________ UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 _________________________ FORM 10-Q _________________________ (Mark One) ☒ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended September 30, 2024 OR ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from _________ to _________ Commission File Number 001-40532 __ ...

Drug Development and Approval - The U.S. FDA accepted the New Drug Application (NDA) for LNZ100 for presbyopia treatment, with a PDUFA target action date of August 8, 2025[3]. - LNZ100 demonstrated a statistically significant improvement, with 74% of patients achieving three-lines or greater improvement in Best Corrected Distance Visual Acuity (BCDVA) at near in the Phase 3 study in China[4]. Financial Performance - Cash, cash equivalents, and marketable securities totaled $217.2 million as of September 30, 2024, expected to fund operations to post-launch positive operating cash flow[7]. - Research and Development (R&D) expenses decreased to $6.5 million for Q3 2024, down from $17.0 million in Q3 2023, primarily due to the conclusion of the Phase 3 CLARITY study[8]. - Selling, General and Administrative (SG&A) expenses increased to $6.5 million for Q3 2024, compared to $2.9 million in Q3 2023, driven by personnel-related expenses and pre-commercial planning[9]. - Net loss for Q3 2024 was $10.2 million, or $0.38 per share, compared to a net loss of $18.9 million, or $9.62 per share, in Q3 2023[10]. - The company completed a $30 million private placement financing in July 2024 to support its operations[6]. Market Insights and Commercial Strategy - Market research indicated that 82% of surveyed Eye Care Professionals (ECPs) would be likely to prescribe LNZ100 based on its clinical data profile[6]. - The company is preparing for a U.S. commercial launch of LNZ100, with a full commercial leadership team established[5]. - The presbyopia market is significant, with an estimated 128 million people in the U.S. and 400 million in China affected by the condition[2].

Table of Contents UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 _________________________ FORM 10-Q _________________________ (Mark One) ☒ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended June 30, 2024 OR ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from _________ to _________ Commission File Number 001-40532 _________________________ LENZ TH ...

Exhibit 99.1 LENZ Therapeutics Reports Second Quarter 2024 Financial Results Submitted New Drug Application (NDA) to the U.S. Food and Drug Administration (FDA) for LNZ100 for the treatment of presbyopia Announced positive topline and capstone data from the Phase 3 CLARITY study Strengthened financial position with $30 million private placement from Ridgeback Capital in July 2024 Pro forma cash, cash equivalents and marketable securities, inclusive of the private placement, were $226.2 million as of June 30 ...

Table of Contents _________________________ UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 _________________________ FORM 10-Q _________________________ (Mark One) ☒ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended March 31, 2024 OR ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from _________ to _________ Commission File Number 001-40532 ______ ...

Exhibit 99.1 LENZ Therapeutics Reports First Quarter 2024 Financial Results and Provides Business Updates Reported positive topline data from Phase 3 CLARITY study for presbyopia; selected LNZ100 as lead candidate; New Drug Application submission anticipated in mid-2024 Capstone data from Phase 3 CLARITY study to be presented at Key Opinion Leader event planned for June 18, 2024 Completed merger with Graphite Bio and concurrent $53.5 million private placement Cash, cash equivalents and marketable securities ...